PharmaLegacy Laboratories was founded in 2008 as a preclinical Contract Research Organization (CRO) providing specialty pharmacology services in Inflammation/Auto-Immune Diseases, Liver/Metabolic Diseases, Bone/Orthopaedics, and Oncology. The core competency of PharmaLegacy stems from our pioneering work and expertise in developing and running specialized animal disease models to test drug candidates and medical devices for their pharmacological effects and biocompatible repairs. Our animal disease models cover a wide range of species from rodents to Non Human Primates (NHP). Our unique NHP disease models form one of the key strengths of our services. We also conduct adjacency studies in PK/PD, molecular pharmacology and preliminary toxicology. Overall we provide one-stop shopping of preclinical pharmacology services from early proof of concept of therapeutics to fulfillment of regulatory requirements.
PharmaLegacy provides quality services with faster turnaround and higher productivity of R&D to IND/IDE endeavors for pharmaceutical, biotech, and orthopaedic device companies around the world.
Backed by a US private equity investment firm, PharmaLegacy is strategically located in the heart of the Biotech and Pharmaceutical base of Zhangjiang High Tech Industrial Park, Shanghai. We have a 45,000 ft2 facility with 17,000 ft2 of SPF and conventional vivarium which are accredited by AAALAC to house 10,000 rodents and 360 large animals.